Bullseye Asset Management LLC Purchases 79,244 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Bullseye Asset Management LLC raised its position in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 58.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 214,264 shares of the company's stock after buying an additional 79,244 shares during the period. Bullseye Asset Management LLC owned 0.43% of Cryoport worth $1,737,000 as of its most recent filing with the SEC.

Other hedge funds have also recently modified their holdings of the company. Thematics Asset Management grew its holdings in shares of Cryoport by 176.2% in the third quarter. Thematics Asset Management now owns 1,705,000 shares of the company's stock valued at $13,828,000 after acquiring an additional 1,087,800 shares in the last quarter. Fred Alger Management LLC boosted its position in Cryoport by 49.9% in the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company's stock worth $21,887,000 after purchasing an additional 898,481 shares during the last quarter. AXA S.A. grew its stake in Cryoport by 274.2% in the 2nd quarter. AXA S.A. now owns 873,217 shares of the company's stock valued at $6,034,000 after purchasing an additional 639,855 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Cryoport by 52.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,477,693 shares of the company's stock valued at $10,211,000 after purchasing an additional 511,064 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Cryoport during the 3rd quarter worth $3,405,000. Institutional investors own 92.90% of the company's stock.

Insider Activity at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total value of $54,972.74. Following the transaction, the director now directly owns 59,497 shares in the company, valued at $443,847.62. This represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the completion of the transaction, the chief executive officer now owns 731,897 shares in the company, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on CYRX. UBS Group increased their price target on shares of Cryoport from $7.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday, October 18th. Roth Mkm reduced their target price on shares of Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Cryoport currently has an average rating of "Moderate Buy" and an average price target of $12.50.

Cryoport Stock Performance

NASDAQ CYRX traded down $0.03 during trading on Tuesday, hitting $8.30. 511,355 shares of the company's stock traded hands, compared to its average volume of 565,390. The stock has a market capitalization of $410.27 million, a price-to-earnings ratio of -2.46 and a beta of 1.62. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The business has a 50 day moving average of $7.32 and a 200-day moving average of $8.14. Cryoport, Inc. has a 12-month low of $5.32 and a 12-month high of $20.10.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.